{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:56:06Z","timestamp":1773993366042,"version":"3.50.1"},"reference-count":52,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"unspecified","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-COHO-002, Observatoire Fran\u00e7ais de la Scl"],"award-info":[{"award-number":["ANR-10-COHO-002, Observatoire Fran\u00e7ais de la Scl"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-21-RHUS-0014, Projection in Multiple sclerosis"],"award-info":[{"award-number":["ANR-21-RHUS-0014, Projection in Multiple sclerosis"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,20]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To determine prognostic factors of disability in multiple sclerosis (MS), that is, (1) identify determinants of the dynamics of disability progression; (2) study the effectiveness of disease-modifying treatments (DMTs); (3) merge determinants and DMTs for creating patient-centred prognostic tools and (4) conduct an economic analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Individuals registered in the French Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP) database were included in this OFSEP-high definition cohort if they had a diagnosis of MS, were \u226515 years old and had an Expanded Disability Status Scale (EDSS) score &lt;7. The outcomes will be assessed annually: (1) time to reach irreversible EDSS scores of 4, 6 and 7; (2) relapses and disease progression; (3) MRI-based progression, patient-reported outcomes, social consequences; and (4) combined outcomes on activity and progression. Clinical and quality-of-life data, MRI results and biological (blood, serum) samples will be collected at each follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings to date<\/jats:title>\n                    <jats:p>A cohort of 2842 individuals, 73.4% women, mean (SD) age of 42.7 (11.6) years, median disease duration of 8.8 years, has been recruited from July 2018 to September 2020. The course of MS was relapsing remitting in 67.7%, secondary progressive in 11.9%. The mean annual relapse rate was 0.98. The disease-modifying treatment received was highly effective therapy in 50.3% and moderately effective therapy in 30.7%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Future plans<\/jats:title>\n                    <jats:p>The participants will be followed until December 2026. Disease course up to four landmarks will be examined as predictors of disease progression: (1) diagnosis of MS; (2) relapse activity worsening and independent progression; (3) any recent disease activity and (4) any visit with absence of disease activity in the past 5 years. The marginal effectiveness and tolerability of treatments will be assessed. Stratified algorithms will be proposed for medical decision-making. Economic evaluation of disease cost and cost-effectiveness of new DMTs will be conducted from a public payer perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03603457\">NCT03603457<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-094688","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:41:35Z","timestamp":1744062095000},"page":"e094688","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic factors of disability progression in multiple sclerosis in real life: the OFSEP-high definition (OFSEP-HD) prospective cohort in France"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03603457","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03603457","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-7024","authenticated-orcid":false,"given":"Francis","family":"Guillemin","sequence":"first","affiliation":[{"name":"CHRU, INSERM, Universit\u00e9 de Lorraine, CIC Clinical Epidemiology, Nancy, Grand Est, France"},{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Casey","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Epstein","sequence":"additional","affiliation":[{"name":"CHRU, INSERM, Universit\u00e9 de Lorraine, CIC Clinical Epidemiology, Nancy, Grand Est, France"},{"name":"Universit\u00e9 de Lorraine, INSERM, INSPIIRE, Paris, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohann","family":"Foucher","sequence":"additional","affiliation":[{"name":"CIC 1402 INSERM, CHU de Poitiers, Universit\u00e9 de Poitiers, Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Laplaud","sequence":"additional","affiliation":[{"name":"CHU Nantes, Service de Neurologie, CRC-SEP, Nantes Universit\u00e9, INSERM, CIC 1413, Center for Research in Transplantation and Translational Immunology, UMR 1064, F-44000, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Achit","sequence":"additional","affiliation":[{"name":"CHRU, INSERM, Universit\u00e9 de Lorraine, CIC Clinical Epidemiology, Nancy, Grand Est, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Rollot","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Leray","sequence":"additional","affiliation":[{"name":"Univ Rennes, EHESP, CNRS, INSERM, Ar\u00e8nes\u2014UMR 6051, RSMS (Recherche sur les Services et Management en Sant\u00e9)\u2014U 1309, Rennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"2025121219365269000_15.4.e094688.1","doi-asserted-by":"publisher","DOI":"10.1177\/135245852097084"},{"key":"2025121219365269000_15.4.e094688.2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.neurol.2023.12.007","article-title":"Prevalence of multiple sclerosis in France in 2021: Data from the French health insurance database","volume":"180","author":"Pierret","year":"2024","journal-title":"Rev Neurol (Paris)"},{"key":"2025121219365269000_15.4.e094688.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30481-1"},{"key":"2025121219365269000_15.4.e094688.4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.euroneuro.2011.08.008","article-title":"Cost of disorders of the brain in Europe 2010","volume":"21","author":"Gustavsson","year":"2011","journal-title":"Eur Neuropsychopharmacol J"},{"key":"2025121219365269000_15.4.e094688.5","first-page":"20552173221093219","article-title":"The socioeconomic impact of multiple sclerosis in France: Results from the PETALS study","volume":"8","author":"Bouleau","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2025121219365269000_15.4.e094688.6","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa145"},{"key":"2025121219365269000_15.4.e094688.7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1352458519892555","article-title":"Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment","volume":"26","author":"Cohen","year":"2020","journal-title":"Mult Scler"},{"key":"2025121219365269000_15.4.e094688.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.26858"},{"key":"2025121219365269000_15.4.e094688.9","doi-asserted-by":"crossref","unstructured":"Reeve K , On BI , Havla J , et al . Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis. Cochrane Database Syst Rev 2023;9. doi:10.1002\/14651858.CD013606.pub2","DOI":"10.1002\/14651858.CD013606.pub2"},{"key":"2025121219365269000_15.4.e094688.10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing Definitions for Progression Independent of Relapse Activity in Multiple Sclerosis: A Systematic Review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol"},{"key":"2025121219365269000_15.4.e094688.11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/01.wnl.0000250347.51674.d7","article-title":"More severe disability of North Africans vs Europeans with multiple sclerosis in France","volume":"68","author":"Debouverie","year":"2007","journal-title":"Neurology (ECronicon)"},{"key":"2025121219365269000_15.4.e094688.12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1590\/0004-282X20160118","article-title":"Disability and progression in Afro-descendant patients with multiple sclerosis","volume":"74","author":"Auren\u00e7\u00e3o","year":"2016","journal-title":"Arq Neuropsiquiatr"},{"key":"2025121219365269000_15.4.e094688.13","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.lpm.2015.01.001","article-title":"Environmental factors in multiple sclerosis","volume":"44","author":"Pantazou","year":"2015","journal-title":"La Presse M\u00e9dicale"},{"key":"2025121219365269000_15.4.e094688.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.10.046"},{"key":"2025121219365269000_15.4.e094688.15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1179\/1476830514Y.0000000117","article-title":"The association of diet with quality of life, disability, and relapse rate in an international sample of people with multiple sclerosis","volume":"18","author":"Hadgkiss","year":"2015","journal-title":"Nutr Neurosci"},{"key":"2025121219365269000_15.4.e094688.16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.msard.2019.01.045","article-title":"Prognostic factors of disability in relapsing remitting multiple sclerosis","volume":"30","author":"Briggs","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2025121219365269000_15.4.e094688.17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00632"},{"key":"2025121219365269000_15.4.e094688.18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7224\/1537-2073.2020-133","article-title":"NARCOMS and other registries in multiple sclerosis: issues and insights","volume":"23","author":"Marrie","year":"2021","journal-title":"Int J MS Care"},{"key":"2025121219365269000_15.4.e094688.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.20235"},{"key":"2025121219365269000_15.4.e094688.20","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-102"},{"key":"2025121219365269000_15.4.e094688.21","doi-asserted-by":"crossref","unstructured":"Massetti M , Aball\u00e9a S , Videau Y , et al . A comparison of HAS & NICE guidelines for the economic evaluation of health technologies in the context of their respective national health care systems and cultural environments. J Mark Access Health Policy 2015;3. doi:10.3402\/jmahp.v3.24966","DOI":"10.3402\/jmahp.v3.24966"},{"key":"2025121219365269000_15.4.e094688.22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s41669-020-00250-7","article-title":"National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison","volume":"5","author":"Sharma","year":"2021","journal-title":"Pharmacoecon Open"},{"key":"2025121219365269000_15.4.e094688.23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/1352458518815602","article-title":"Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"key":"2025121219365269000_15.4.e094688.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025121219365269000_15.4.e094688.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(00)00104-5"},{"key":"2025121219365269000_15.4.e094688.26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.8.671"},{"key":"2025121219365269000_15.4.e094688.27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neurad.2014.12.001","article-title":"Imaging Working Group of the Observatoire Fran\u00e7ais de la Scl\u00e9rose en Plaques. OFSEP, a nationwide cohort of people with multiple sclerosis: Consensus minimal MRI protocol","volume":"42","author":"Cotton","year":"2015","journal-title":"J Neuroradiol Juin"},{"key":"2025121219365269000_15.4.e094688.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurad.2020.01.083"},{"key":"2025121219365269000_15.4.e094688.29","doi-asserted-by":"crossref","first-page":"104872","DOI":"10.1016\/j.msard.2023.104872","article-title":"The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers","volume":"77","author":"Brocard","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025121219365269000_15.4.e094688.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102512"},{"key":"2025121219365269000_15.4.e094688.31","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513480251"},{"key":"2025121219365269000_15.4.e094688.32","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65 Suppl 4","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2025121219365269000_15.4.e094688.33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2025121219365269000_15.4.e094688.34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"2025121219365269000_15.4.e094688.35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology. Avr"},{"key":"2025121219365269000_15.4.e094688.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011163432001"},{"key":"2025121219365269000_15.4.e094688.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00109-7"},{"key":"2025121219365269000_15.4.e094688.38","unstructured":"Hays RD , Prince-Embury S , Chen HY . RAND-36 Health Status Inventory. San Antonio, TX: The Psychological Corporation, 1998."},{"key":"2025121219365269000_15.4.e094688.39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.neurol.2010.10.008","article-title":"French validation of the Multiple Sclerosis International Quality of Life Questionnaire","volume":"167","author":"Baumstarck-Barrau","year":"2011","journal-title":"Rev Neurol (Paris)"},{"key":"2025121219365269000_15.4.e094688.40","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121219365269000_15.4.e094688.41","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0322-4"},{"key":"2025121219365269000_15.4.e094688.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70021-3"},{"key":"2025121219365269000_15.4.e094688.43","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517703193"},{"key":"2025121219365269000_15.4.e094688.44","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"2025121219365269000_15.4.e094688.45","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509104591"},{"key":"2025121219365269000_15.4.e094688.46","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512460605"},{"key":"2025121219365269000_15.4.e094688.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.10.018"},{"key":"2025121219365269000_15.4.e094688.48","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"2025121219365269000_15.4.e094688.49","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2174\/1570159X22666240124114126","article-title":"Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?","volume":"22","author":"Bellanca","year":"2024","journal-title":"Curr Neuropharmacol"},{"key":"2025121219365269000_15.4.e094688.50","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/13524585221139156","article-title":"Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system","volume":"29","author":"Sabath\u00e9","year":"2023","journal-title":"Mult Scler"},{"key":"2025121219365269000_15.4.e094688.51","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-022-01660-3","article-title":"Individual dynamic prediction of clinical endpoint from large dimensional longitudinal biomarker history: a landmark approach","volume":"22","author":"Devaux","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2025121219365269000_15.4.e094688.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.05.007"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-094688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T03:36:59Z","timestamp":1765597019000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-094688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,7]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/bmjopen-2024-094688"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-094688","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}